-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 L4UxHW8lrX3Gl7ryMaWy9JZeBQDvJdGC8OiNGal4uPFKdX1201F9UqrvkI0cCtHW
 w+9Cm4Q/+egleLMciv4HsA==

<SEC-DOCUMENT>0001178913-09-000611.txt : 20090317
<SEC-HEADER>0001178913-09-000611.hdr.sgml : 20090317
<ACCEPTANCE-DATETIME>20090317073031
ACCESSION NUMBER:		0001178913-09-000611
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090317
FILED AS OF DATE:		20090317
DATE AS OF CHANGE:		20090317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		09686359

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk96537.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\office\EDGAR Filing\Compugen Ltd\96537\a96537.eep       -->
     <!-- Control Number: 96537                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 6-K </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=4>SECURITIES AND EXCHANGE COMMISSION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant
to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2> for the month of March 2009</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>72 Pinchas Rosen
Street, Tel-Aviv 69512, Israel </U></FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Address of principal executive offices) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Form 20-F   <FONT size="3" face="Wingdings">x
</font>   Form 40-F <FONT size="3" face="Wingdings">o
</font></FONT></P>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On March 17, 2009 Compugen Ltd. (the
&#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on Form
6-K, which is hereby incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>

<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR>
<BR>By: /s/ Ms. Dikla Czaczkes Axselbard<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ms. Dikla Czaczkes Axselbard<BR>Title:  Chief Financial Officer<BR>Date: March 17, 2009</FONT></TD>
</TR>
</TABLE>
<BR>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\office\EDGAR Filing\Compugen Ltd\96537\a96537.eep       -->
     <!-- Control Number: 96537                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U><B>Exhibit 1</B></U> </FONT> </H1>


<IMG SRC="compugenb.jpg"><BR><BR>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For Release </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<p ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Compugen Announces
Positive Therapeutic Effects of</B> </FONT> <BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Relaxin Receptor Peptide Ligand in Pulmonary Fibrosis Animal Model</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Relaxin receptor
is third GPCR for which Compugen novel</B> </FONT> <BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>peptide
ligands have demonstrated proof of efficacy in animal models</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Tel-Aviv, Israel, March 17, 2009
&#150; </B> Compugen Ltd. (NASDAQ: CGEN)  announced today that CGEN-25009, a novel peptide that previously
demonstrated the ability to activate the Relaxin receptor LGR7 (RXFP1) in cell based
assays, has shown positive therapeutic effects in an animal model of pulmonary fibrosis.
The Relaxin receptor is the third G-protein coupled receptor (GPCR) for which
Compugen-discovered peptide ligands have shown therapeutic potential in disease models. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#147;Following two weeks of
administration of the CGEN-25009 peptide to mice induced with lung fibrosis, there was a
complete reduction in the fibrosis. This improvement was evident both by histology
staining and by measuring the Pressure at the Airway Opening (PAO), where levels were
comparable to those observed in healthy mice,&#148; said Dr. Anat Cohen-Dayag, vice
president, research and development. &#147;These results suggest that CGEN-25009 prevents
pulmonary fibrosis in a disease animal model and therefore could have a potential
therapeutic utility to treat pulmonary fibrosis and other fibrosis related conditions,
such as chronic renal failure.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Professor Daniele Bani from the
University of Florence, Italy, who performed the animal study and is a recognized world
expert in this field with numerous publications on Relaxin&#146;s biology and pathway
added, &#147;To my knowledge, this would be the first report on the therapeutic
effectiveness of an analogue of Relaxin. In view of the increasing interest in Relaxin as
a possible drug and considering the problems inherent in producing enough of this hormone
at a reasonably low cost, it could be foreseen that such information would be
enthusiastically welcomed.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pulmonary fibrosis is a devastating
incurable condition, the cause for which is unknown in most cases. It is estimated to
affect more than five million people worldwide with tens of thousands of new cases every
year in the United States. More than 60% of patients diagnosed with the condition survive
less than five years. </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In 2007, Compugen announced the
development of its GPCR Ligand Discovery Platform and its subsequent validation through
the prediction and selection of several novel peptides that specifically activate various
GPCRs. The GPCR family of membrane protein receptors is the largest family of known drug
targets and therefore is of high interest in the pharmaceutical industry. At least 40% of
prescription drugs currently available are thought to act on GPCRs. Furthermore, newly
discovered GPCR peptide ligands have in the past shown a high probability of being
successfully developed into new drugs. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CGEN-25009, along with two other
Relaxin related peptides, CGEN 25010 and 25011, were among the first peptide ligands
predicted and selected utilizing Compugen&#146;s GPCR Ligand Discovery Platform. These
peptides were first presented in May 2008 at the 5<SUP>th</SUP> International Conference
on Relaxin and Related Peptides. Compugen&#146;s initial results suggested that CGEN-25009
has biological activities similar to those of Relaxin, which are now further supported by
the in-vivo findings. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr. Yossi Cohen, Compugen&#146;s chief
technology officer added &#147;The growing body of positive results for the initial
peptides predicted by our GPCR Ligand Discovery Platform is extremely encouraging. In
February of last year we announced positive in-vivo results for two peptide ligands of the
MAS GPCR indicating cardio-protective effects and therapeutic potential for the treatment
of various cardiovascular diseases. These results were presented at the VII International
Symposium on Vasoactive Peptides. In addition, a few months ago we announced the signing
of a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck
Serono, covering a peptide ligand for the FPRL1 GPCR, which was shown in experimental
studies to have potential to treat inflammatory diseases and other indications.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush Lv 0- TNR" FSL="Workstation" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr.
          Cohen continued, &#147;Subsequent runs of our GPCR ligand platform have yielded
          additional putative peptide candidates. Furthermore, the platform is the basis
          of our existing collaboration with Merck &amp; Co. and the subject of current
          discussions with additional potential partners. Given this record of early and
          growing successful validation and industry interest, and the importance of GPCRs
          in medicine, we have high expectations for this discovery platform.&#148; </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About LGR7, the Relaxin
Receptor</B><BR>Substantial world-wide research
efforts have recently demonstrated that the natural peptide hormone Relaxin is
multi-functional and applicable to a broad range of target tissues, including the
reproductive system and other organs, in addition to its historical role as the
&#147;pregnancy hormone&#148;. Known to activate the LGR7 and LGR8 GPCR receptors, the
currently recognized diverse and vital roles of Relaxin include anti-fibrotic activity,
homeostatic roles in reproductive health, fertility and ageing, as well as the exhibition
of therapeutic properties in various pathophysiological conditions such as infertility,
pregnancy and labor complications, cardiovascular diseases, inflammatory disorders, wound
healing and fibrotic diseases. </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen&#146;s
GPCR Peptide Ligand Discovery Platform</B><BR>Compugen&#146;s GPCR Peptide Ligand
Discovery Platform relies on a series of sequential computational biology models and
machine learning capabilities for the prediction and selection of product candidates. The
platform incorporates a proprietary model of the &#147;peptidome&#148;, an <I>in
silico</I> prediction of putative human peptides. Compugen&#146;s proprietary peptidome,
which includes thousands of novel predicted human peptide sequences, is based on
predicting cleavage sites in precursor proteins. The discovery platform utilizes
proprietary machine-learning algorithms to analyze this peptidome and to identify peptides
likely to activate GPCRs. Subsequently, selected molecules undergo several experimental
validation stages. </FONT> </P>

<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen</B> <BR>Compugen is a leading drug and
diagnostic product candidate discovery company. Unlike traditional high throughput trial
and error experimental based discovery, Compugen&#146;s discovery efforts are based on
<I>in-silico</I> (by computer) prediction and selection utilizing a growing number of
field focused proprietary discovery platforms accurately modeling biological processes at
the molecular level. The resulting product candidates are then validated through <I>in
vitro</I> and <I>in vivo</I> experimental studies and out-licensed for further development
and commercialization under various forms of revenue sharing agreements. Compugen&#146;s
current collaborations include Biosite, Medarex, Inc., Merck &amp; Co., Inc., Merck
Serono, Ortho-Clinical Diagnostics (a Johnson &amp; Johnson company), Roche, Siemens
Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen
established an affiliate, Evogene Ltd. <U>www.evogene.com</U> (TASE: EVGN.TA), to utilize
certain of the Company&#146;s <I>in-silico</I> predictive discovery capabilities in
agricultural biotechnology. For additional information about Compugen, please visit the
Company&#146;s corporate Web site at <U>www.cgen.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may,&#148;
&#147;expects,&#148; &#147;anticipates,&#148; &#147;believes,&#148; and
&#147;intends,&#148; and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>


<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Company contact:
</B><BR>Marjie Hadad
<BR>Global Media Liaison
<BR>Compugen Ltd.
<BR>Email: marjie@cgen.com
<BR>Tel: +972-54-536-5220 </FONT>
</P>


<p align=center>
<font size=2>3</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugenb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugenb.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`;O7.WOV'K0!Q/Q+\>ZOX5U&"RTSX<>*O$YD0N\VE
M10^7%Z`M(ZY/TH`\;^(`@\:>(7UG7_@=\:FN&0($M-?DM8D4=ECANU0?ES0!
MB2^%O#B0,TGP-^.BHHRQ?Q==!0/<F^P!0!RGC>UM+;3H?^$'^!OQ%U.^ED"M
M'J/Q(GMT`[;=EZS,Q.,`"@#Z`_9S^#^A^'K6P\;ZUX.&F>,I;8QNMSKEWJQL
M48Y,<<MPS%6(QNV@#.1DB@#V*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`/"OCC\3M+U3[?X//A_XOVB6ESL?5/"NG21&;8>0DP&=A/=<
M9QUQ0!Y>+GPX/^6W[57T^U7G^-`#EG\.$<2_M4_^!=Y_C0!Y_P#$B]UC5/[0
M\/\`_"J/VBO$WAZX'EG^T_%<\*W2?[<)C;C/8DT`;7[%?P9\":G\9[76;SX`
M^,O!TOAH+J-I>:]K+7$#SJV$`C,2Y93\X.>"H-`'W30`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$=U&TMM)&DK0LZE5D3&5)'49XXH`^4
M?&]W'X2\4W?AW6OVEOC+'?6+!9%M_"K7$?(##;)'9,K#!'()H`R/^$KT?_HY
MOXV_^$;/_P#(%`%;6=>\.ZEHUYIE[^TK\;IK:\A>&:(>#[A"Z,,$!A8@KD$C
M((H`^=SH7@@$JNC_`+3CA3C<@AP?<90'\P*`/3?V5/'?AGX1_$<ZM;>%?C[=
MVNIQK97?]NV4=Q;P1EU/G%8T\SY.3A>2">"<"@#]!].NH+VP@O;60207$:R1
MNO1E(R#0!-0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&;
MXNL=4U'P]=66BZT^C7TJ8AOT@28PMV.QQM;Z&@#YN^(WQ%O/`/BN?PSXP_:M
MATG5;94:2VG\'1YVL,J00A!!'<$]".H-`&%_POC0_P#H\>Q_\(Y/_C=`',>/
M_'G@_P`97%I+J'[;6HV+V@94_LC1'L@P."=^Q1NZ<9Z<T`>.M\5?#Z2.B_&W
M]HR3:Q&^+3[5D;'=3]JY![&@#TS]E3]HKPQX5^)EIIM[XZ^,7B*SUZ>.R:#Q
M+HUMY,,KL%23S5N&=`"><`Y!Z<4`??M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'@7QI^*MO\`\)6MKX+_`&A?A-X;CLD,%[9:S)%<
M3B<,<\B==N!QM(SG-`'(?\+1\6?]'7_`K_P'C_\`DF@!5^*'BLG!_:O^!6.X
M^SQ]/_`F@#PKXG?'K5;SQK>,G[7[:=]G(MS%X?\`"TALV*\%T)<[@?[P.#0!
MH?`KQUXP^('Q8T/POH/[6_B76KFZN5DDLE\,O$)(D.^3<Y;"#:",GUH`_1"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R=5\4^&=+OFLM2\
M1Z39W*`%H+B\CC=0>A*D@\T`>=_$CQQXODUI8_`7BOX5Q::JX9];U-VED;'.
M%CX`_$Y]J`.`9?&VXDS?LWY/)SO_`,*`.2^(WQ*7P&\,?B?7/V=+>6?E(;:S
MN+E\>I6-3@>YH`\Z\;_'2TUB&WCT'XK?!;PPT1)DEL_"D]PTOH#YT+``>PS[
MT`:7PB3XR_%&\FM/`'QL^'NK_9P3)/'X&1((SZ&1K4+N]LYH`^P?@=X'U+P=
MX3AB\2:Q9:[X@D&;O4K?2K>Q4YYV(D*+\@/3=DGK[``[B@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#SGXC>,/B1IOB)[/P;X)\,ZSIZ(-UWJ/
MB;[$^_\`B41B"3@>I(^E`'DNI>$M4U'49]0U+]E[X,WMY=2&2:YN?$D<DDC'
MJ69K$DGW)H`KS>"6BA>67]E3X'QQQJ6=V\0P@*!U)/V#I0!X?\2]?T/4KR!?
M!.E?LJ^$H(AB9+BXM=2DF;_>DME"K[!<^_:@#'\-6/C/7M>M=%T#6?V6]1U.
M_D\JWM+/1K!Y97ZX`$'I0!],?L__`+-^K(PU/XR:-\,+D@,JZ)H?A"QCC]`T
MEQY>\]<[5"]!DGD4`?1/AO1=(\/:/#I6A:79:98VXQ':V4"PQ)]%4`"@"_0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?)4GPE>25Y)/V/-&
M9W8LS-XTC)8DY)/R^M`"?\*B_P"K.M$_\+./_P")H`JZW\([H:-=&Q_9`\,P
M7(B;RY;[Q>CP(<<,Z@`E1W&10!X[#X"\9R,L<?P7_9G>1B%"KJH)8]@!]KZF
M@#["_96^#6C?#_P[!KVI^!_!VA^,KV$I>OX;MG2&%"<B)&=W8XXW,",D>@%`
M'G/[57[;G@KX4^([KPEX:T:7Q;XALSLN!#.L5I:OG&QI`&+..ZJOMD&@#RC1
M_P#@H7XRT'Q:FG_$KX0+86QVR216DLL%U#$PR'"3##\<@94'U%`'U3\7_P!H
M/X<?#CX/Z;\1M:U-Y]-URWCN-*MK10UQ?[T#J$4D=B,DD`=S0!\GZ]_P4<\1
MR7KWF@?"*V31X9!&TM[?R.S$\X+)&%0D=N?QH`^B_P!D7]J;P;\<],U1(M.N
MO#NM:';_`&N]TZZD$J>3T,L<@`W*#@'(4@D<<YH`\'T__@HX9O%L6FS?"ZW@
MT][L0-?+K#R%8]^"X1;?+''(4=>E`&?XO_X*.ZM:^/98M#^&5JWA^VG,;)J%
MV\=[,@/7@;8F(_A(;'K0!I?&/_@HHECJEO:_#?P$+RU,4<TE[KDCQ;]P!*I$
MO.!R-Y;!P>,=0#V*X_:NT]?V)E^/4'A=GN!*EF=&FN?+#W!E$;A9=IRH!9@=
MO(&.*`/(/#G_``4>MKJPU634OA+=0W-K;^99V]GJ?G"9\\^8YB7RD`Y+8;Z4
M`=1^R-^W"_Q4^+MGX!\4>"[719]7+BQO;.],B;PI81NK*.2`?F!Z]J`*'Q[_
M`&^C\/OC)XB\$:9\,XM9@T&\-F+YM7,)F=0`_P`@A;&'W`<G.!0!U'[4/[8E
M_P#!N/P;;7/PZAU'4_$NC)JUU:G5#"++<<",'RF+\AADA>G2@#I?A=^U/I.J
M_LLWGQQ\>:"OA;2XKN2TM+*&Z^U2WK+PHCRB99FW`#H`I)(`.`#PG2?^"C>J
M7/C))KCX3^5X6A_X^S;7C37D*$X$@;8J<#^$@9/&X4`=-\%?V]-5^(WQE\/>
M`]/^$L5N-=U&.T^UG62QBB+9>39Y`R50,VW(Z8S0!WG[6W[9_@SX->*)/!^D
MZ'<>*_$MOL-S:P7"PP6N[^"27#'S,$':%/7DB@#R70_^"AOB#2/%<-C\1?A`
M^EV4Q21OL]S(ES#"V<2".5`)./=<X-`'LO[8G[6%A\%M#\&:GHGAJ+Q5#XSM
MI+VW;[<;4+`JQLK_`.K8G<)1C('0T`>/3_\`!1H-\/)]2A^&.S76O/LT-H;]
MWMHH]@;S)9?*7EB2%C4$G8Y)7Y=P!ZW^P+^U'>_'R\US0]>\,V^D:OHT:70D
ML9&:":%FV]&Y5@?<@@]L4`?2M`'SA\9O`?AK3/'=U+'\)?BEXG;4F:]EOM`U
ML+;B1V)9`KW494@]@N,$8]@#E/\`A&?#W_1N_P`<_P#P=Q__`"=0`V;PKX:F
MB>&7]G/XXO'(I5D;6HB&!X((^W=*`//_`(6?!^X'[0VC02_LI6&@>&UU,2PZ
MKJFJ$7,,*G<CM"+AE9QA<@;AF@#[@^).I7>C?#K7M7LHS)=:?I]Q<PJHR2Z1
MLR\#W%`'X[_LD6%CXM_:O\#P^*-4MXH+W7(KR[N+YP$G=6,VQB>"9'4)[EP.
M]`'U9^T5\6?V2/&OQWOX/$OP]\3>,/$,,R:3'>:4ZM#=NIVHL1$P#?,2`<<F
M@#R#_@J:'T?XZ:#X#LX'L]`\)^'+2VTJR8Y\F,@@Y/.X_*%SD_=H`O>//$O@
MOPS_`,$M?"/@?3-1TR\\1^+-5>^OX+:=&F@,<[L6D7[RX58DY_#(H`SOV&X=
M5\)?!KXS_%=T^SZ7;>&GT.WFD0[9[J9U.U#T.T`9]-ZT`<Y_P3:\+V?B;]KK
MPPFI1K)9Z(DVK2JPR,PQDH3_`,#*T`</XH^T_$W]IF]CA5/.\5>)##&%''[R
M?:/T-`'I/_!3?4]-D_:=G\.:,MNEAX0TNUTB-((@@4JFY@<>A;%`'7?M5'_A
M!O\`@GQ\&_AW'*L<^ONVOWD1^\05+(?I^^_2@#(_8L\2?#[P-^S7\9O$NOZS
MIR>(]2TPZ-IVF2RKY\JRQ.H*1GYF&]QDC@!><4`<U_P39T";5?VK_#^IXD6T
M\+PSZO=R!>$2.)@`3T&2P%`'G&EZG:>+/CY!K?BF_2RL]:\0"[U"[ER4B1Y]
M[D^P!_`4`>A?\%%?B#H_Q#_:AU?4_#6JP:IH6D6=OI6GW=N<QND:;GVG^)?-
M>3##@CD9%`'1?MLV&H>#O@!\"_AZ5EM[2'0IM8GC^8+)=3LI8GL2H)QW`<^M
M`$_P,\>?#7P%^P!\1M/DU.RF\=^-IVTQ=."DW'D[556/&`BJTK@YQGCK@4`5
M?^"7&BSW/[15]XG@LQ<R>$=`O=0@4C(\\IY:#TYW-0!Y7\"M%U_XG?M#:+8Q
M>)X=,U[6]0>\&M7RAUCN`KS>8PZ$EEX]R*`/5?C5X'T/Q9\6)-.^('[5VBZ_
MXJM672@5T*_NOFW';"LD,11L,Y'!."2.H(H`H_\`!1R7^Q_BUX8^&BWYNT^&
M_A+3=#DDVE0TJPAV8#W5HS^G:@#J/CY:Z;X&_P""9_PI\,1VD=OJOC34I-=N
M"8_GE1%<[R>N0LT`'L:`/6/^")7AB2/0/'OC211Y=U=6VEP-GH8D:20?^1HO
MRH`^[:`.<^)W@RQ\;^'/['O=6UW2D$BRBYT349;*<$=O,C(.#GD'B@#SW_AG
M#P__`-%)^+/_`(6%Y_\`%4`'_#.'A_\`Z*3\6?\`PL+S_P"*H`CTG]F'P!:?
M$'0_&MYKOC;6=8\.2^=83ZQK\]WY)ZD#>3\I[CO0![/)&KAE<!E88*D<8H`^
M4?BA^P!\(?$WB&YU71=2UGPW]KF,SVEFRO`I)RP16'RCT&<#M0!V/[/G['GP
M?^$_BF#Q/I]E>ZSK5FV^UN]5E#BV;D;D0`*&YZD$CJ,&@#H/VG/V;OAQ\<;>
MWF\4VMS;:O91^5;:K92;)HTR3L(/#+DYP1QV(H`\9\'_`/!.OX5Z;J8N-<\4
M>(M7A4@_9PR0!L=B5&<?3%`'N_Q'^`_@3Q5\!H_A!;6TV@>&(3&8[?2F",H1
MMV,MDG)Y).2222<F@#D/@)^R1\._A)JNMZEX:U+6I+O6],DTMY;J5&:&-R"Q
M0A1AN!S0!@?"O]AOX3^`_B)HGC'3=3\07-YH5TEY!%<SH8S(ARI("CH<'\*`
M(_B3^PQ\+O&_CW6/%VLZ_P")C?ZU=/=3A+A`H9CT'R].U`'RE_P5HUNS;]H7
M2?!NGLJV7@_1(+.-`1\A;YL?4*%H`]/_`&=_V)?`_P`3_P!F+P9XJU?4=3T+
M7M1@DNI[FS(83Q/(3'N5N`0F,$8X-`'U?^SA\!?A]\%?"EUHOA33Y)9-1Q]N
MOKUO,FNL`@!CT"@$_*!CF@#Q]O\`@G[\&&\>MKC7VO?V8TIE_L43J(AEL[=^
M-VSMC.<=Z`)O$7[`_P`&]6\576MM>ZY:_:KDW!L[:6-((P6R$5=O"@<?2@#@
M/^"F'Q(\`:-XDTOX7_$7X27VL:?IUHEWH^KVNH_99%#*$<(=IX!4!E.0=JG'
M`H`^5OBOXF^`"?!BVT?X8^"M;M/$VIW,<VI:AKDPF-I$F3Y4##&=S;23M!PI
M'>@#[3_X)*?!W5_`?PVUCQIXITJXT[4_%<B);VMTFR1+5`2K,IY&YF)P>P%`
M%GXH_P#!/WX2>)O$MQJV@ZIJWAB.ZD,C6%GLDMXR>HC5A\HSVS@=L"@#L/V?
MOV-?A!\*?%=KXHLX-0UK6;')M[C4Y0Z0L?XUC``##L3G%`&9\7_V)/AG\1OB
M/K7C77]?\2C4M;G,\WE3H$3@*JJ-O0*%`SZ4`='\>?V5O`?Q7TSPKIFN:KK=
MI8^#[`V%A;64JJH4A`6.5/S$1H/PH`[;]FWX1>&O@I\.CX.\+37<UFUU)>/+
M=L&D=WP#D@`<!0/PH`[^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^1_VD_\`
MDM6N?2'_`-%B@#Z5^$'_`"2SP]_V#X?_`$`4`='0`4`%`'S?_P`%.?\`DWZ+
J_K_7_P!!-`'P?_P3B_Y._P##7_;;_P!!-`'[`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
